DNMT inhibitors such as FdCyd require an extended timeframe for activity, given that transition through S phase of the cell cycle is needed to enable inhibitor incorporation into DNA, and human tumors exhibit relatively slow progression through the cell cycle—resulting in tumor volume doubling times in the range of weeks to months [39]. This evidence concerns the gene DNMT1 and neoplasm.